ACT Brief: Bayesian Designs Gain Ground, Data Priorities Take Shape, and Rare Disease Strategy Expands

In today’s ACT Brief, we explore how Bayesian trial designs are gaining traction in rare disease research, what priorities clinical operations leaders should focus on in 2026, and how rare disease science is shaping broader drug development strategies.